ArticleThe oncologist2016

Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.

Letizia Gandolfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.